BERKELEY, Calif., Dec. 13, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that Joseph M. Limber has been appointed to its Board of Directors. Mr. Limber brings over 30 years of unparalleled biotechnology and corporate leadership experience to XOMA's Board, including from his current position as President and Chief Executive Officer of Prometheus Laboratories, a Nestlé Health Science company. "I am pleased to welcome Joe to our Board of Directors," stated John Varian, Chief Executive Officer of XOMA. "Our team is particularly excited to work closely with Joe, as he has successfully developed markets for specialty pharmaceutical products and managed the critical transition from research organization to commercial entity. We expect to make the same transition in the coming years and Joe's insight and guidance while we prepare for a gevokizumab commercial launch will be instrumental to our future success." Mr. Limber led a significant expansion of Prometheus Laboratories' business, both organically through internally developed products and through product acquisitions. He led negotiations to acquire exclusive U.S. commercial rights to ENTOCORT EC from AstraZeneca and Proleukin from Novartis, as well as the purchase of Lotronex from GlaxoSmithKline. Mr. Limber's leadership helped Prometheus Laboratories grow its revenues to over $500 million, representing an approximate 30% CAGR with a 30% operating margin. Prior to joining Prometheus in 2003, Mr. Limber was a consultant and interim Chief Executive Officer of Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was President and Chief Executive Officer of ACLARA BioSciences, Inc., a developer of assay technologies and lab-on-a-chip systems for life science research. From 1996 to 1998, he was the President and Chief Operating Officer of Praecis Pharmaceuticals, a biotechnology company focused on the discovery and development of pharmaceutical products. Prior to Praecis, Mr. Limber served as Executive Vice President of SEQUUS Pharmaceuticals, Inc. He also held management positions in marketing and sales with Syntex Corporation and with Ciba-Geigy Corporation. Prometheus Laboratories was acquired by Nestlé Health Science in July of 2011. Mr. Limber has held seats on the Boards of Directors at numerous companies, including Panacos Pharmaceuticals, Molecular Insight Pharmaceuticals and CombiMatrix Corporation.